Copyright
©The Author(s) 2022.
World J Gastrointest Oncol. Feb 15, 2022; 14(2): 511-524
Published online Feb 15, 2022. doi: 10.4251/wjgo.v14.i2.511
Published online Feb 15, 2022. doi: 10.4251/wjgo.v14.i2.511
Figure 2 Adjusted log relative hazard for chemotherapy compared with no chemotherapy over 10 mo from esophageal cancer diagnosis whereby the effect of chemotherapy on overall survival varies with time and is associated with improved overall survival up until 10 mo, after which there is no chemotherapy effect on overall survival.
Dashed lines represent estimated 95% confidence intervals of the hazard ratios (HRs). The dotted horizontal line denotes no chemotherapy effect. The adjusted HR is estimated by a multivariable model including chemotherapy, age, gender, race, insurance type, treatment site, geographic location, number of comorbidities, grade, and American Joint Committee on Cancer T stage.
- Citation: Midthun L, Kim S, Hendifar A, Osipov A, Klempner SJ, Chao J, Cho M, Guan M, Placencio-Hickok VR, Gangi A, Burch M, Lin DC, Waters K, Atkins K, Kamrava M, Gong J. Chemotherapy predictors and a time-dependent chemotherapy effect in metastatic esophageal cancer. World J Gastrointest Oncol 2022; 14(2): 511-524
- URL: https://www.wjgnet.com/1948-5204/full/v14/i2/511.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v14.i2.511